Molecular properties determining unbound intracellular and extracellular brain exposure of CNS drug candidates

Molecular Pharmaceutics

Volumn 12, Issue 2, 2015, Pages 520-532

  Loryan, Irena ^a   Sinha, Vikash ^b   Mackie, Claire ^b   Van Peer, Achiel ^b   Drinkenburg, Wilhelmus H ^b   Vermeulen, An ^b   Heald, Donald ^c   Hammarlund Udenaes, Margareta ^a   Wassvik, Carola M ^b,d  

^a UPPSALA UNIVERSITY   (Sweden)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

BBB drug transport; binding and distribution in the brain; blood brain barrier (BBB); brain drug delivery; in silico modeling; intracellular accumulation; neuropharmacokinetics; PLS analysis

Indexed keywords

BAY 60 7550; CENTRAL NERVOUS SYSTEM AGENTS; CYANO PYRIDINE 2 CARBOXYLIC ACID [3 (5 AMINO 3 DIFLUOROMETHYL 3,6 DIHYDRO 2H [1,4]OXAZIN 3 YL) PHENYL ] AMIDE; LY 2811376; LY 2886721; OLANZAPINE; PALIPERIDONE; RISPERIDONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN HOMOGENATE; COMPUTER MODEL; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG TRANSPORT; HYDROGEN BOND; LIPOPHILICITY; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; ANIMAL; BRAIN; HUMAN; MALE; METABOLISM; SPRAGUE DAWLEY RAT; STATISTICAL MODEL;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM AGENTS; HUMANS; MALE; MODELS, STATISTICAL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84928648975     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp5005965     Document Type: Article

References (41)

1. Hammarlund-Udenaes, M. Active-site concentrations of chemicals-are they a better predictor of effect than plasma/organ/tissue concentrations? Basic Clin. Pharmacol. Toxicol. 2010, 106 (3) 215-20
2. Hammarlund-Udenaes, M.; Friden, M.; Syvanen, S.; Gupta, A. On the rate and extent of drug delivery to the brain Pharm. Res. 2008, 25 (8) 1737-50
3. Friden, M.; Bergstrom, F.; Wan, H.; Rehngren, M.; Ahlin, G.; Hammarlund-Udenaes, M.; Bredberg, U. Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods Drug Metab. Dispos. 2011, 39 (3) 353-62
4. Friden, M.; Gupta, A.; Antonsson, M.; Bredberg, U.; Hammarlund-Udenaes, M. In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids Drug Metab. Dispos. 2007, 35 (9) 1711-9
5. Kalvass, J. C.; Olson, E. R.; Cassidy, M. P.; Selley, D. E.; Pollack, G. M. Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: assessment of unbound brain EC50,u and correlation of in vitro, preclinical, and clinical data J. Pharmacol. Exp. Ther. 2007, 323 (1) 346-55
6. Liu, X.; Van Natta, K.; Yeo, H.; Vilenski, O.; Weller, P. E.; Worboys, P. D.; Monshouwer, M. Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid Drug Metab. Dispos. 2009, 37 (4) 787-93
7. Fridén, M. Prediction of Drug Exposure in the Brain from the Chemical Structure. In Drug Delivery to the Brain; Hammarlund-Udenaes, M.; de Lange, E. C. M.; Thorne, R. G., Eds.; Springer: New York, 2014; Vol. 10, pp 317-338.
8. Young, R. C.; Mitchell, R. C.; Brown, T. H.; Ganellin, C. R.; Griffiths, R.; Jones, M.; Rana, K. K.; Saunders, D.; Smith, I. R.; Sore, N. E. Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists J. Med. Chem. 1988, 31 (3) 656-71
9. Liu, X.; Tu, M.; Kelly, R. S.; Chen, C.; Smith, B. J. Development of a computational approach to predict blood-brain barrier permeability Drug Metab. Dispos. 2004, 32 (1) 132-9
10. van de Waterbeemd, H.; Smith, D. A.; Jones, B. C. Lipophilicity in PK design: methyl, ethyl, futile J. Comput.-Aided Mol. Des 2001, 15 (3) 273-86
11. Sagare, A. P.; Bell, R. D.; Zlokovic, B. V., Neurovascular dysfunction and faulty amyloid beta-peptide clearance in Alzheimer disease. Cold Spring Harbor Perspect. Med. 2012, 2 (10).
12. Liu, X.; Vilenski, O.; Kwan, J.; Apparsundaram, S.; Weikert, R. Unbound brain concentration determines receptor occupancy: a correlation of drug concentration and brain serotonin and dopamine reuptake transporter occupancy for eighteen compounds in rats Drug Metab. Dispos. 2009, 37 (7) 1548-56
13. Friden, M.; Winiwarter, S.; Jerndal, G.; Bengtsson, O.; Wan, H.; Bredberg, U.; Hammarlund-Udenaes, M.; Antonsson, M. Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids J. Med. Chem. 2009, 52 (20) 6233-43
14. Kalvass, J. C.; Maurer, T. S. Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery Biopharm. Drug Dispos. 2002, 23 (8) 327-38
15. Chen, H.; Winiwarter, S.; Friden, M.; Antonsson, M.; Engkvist, O. In silico prediction of unbound brain-to-plasma concentration ratio using machine learning algorithms J. Mol. Graphics Model. 2011, 29 (8) 985-95
16. Spreafico, M.; Jacobson, M. P. In silico prediction of brain exposure: drug free fraction, unbound brain to plasma concentration ratio and equilibrium half-life Curr. Top. Med. Chem. 2013, 13 (7) 813-20
17. Loryan, I.; Sinha, V.; Mackie, C.; Van Peer, A.; Drinkenburg, W.; Vermeulen, A.; Morrison, D.; Monshouwer, M.; Heald, D.; Hammarlund-Udenaes, M. Mechanistic understanding of brain drug disposition to optimize the selection of potential neurotherapeutics in drug discovery Pharm. Res. 2014, 31, 2203-19
18. Friden, M.; Ducrozet, F.; Middleton, B.; Antonsson, M.; Bredberg, U.; Hammarlund-Udenaes, M. Development of a high-throughput brain slice method for studying drug distribution in the central nervous system Drug Metab. Dispos. 2009, 37 (6) 1226-33
19. Loryan, I.; Friden, M.; Hammarlund-Udenaes, M. The brain slice method for studying drug distribution in the CNS Fluids Barriers CNS 2013, 10 (1) 6
20. Wan, H.; Rehngren, M.; Giordanetto, F.; Bergstrom, F.; Tunek, A. High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery J. Med. Chem. 2007, 50 (19) 4606-15
21. Hammarlund-Udenaes, M.; Bredberg, U.; Friden, M. Methodologies to assess brain drug delivery in lead optimization Curr. Top. Med. Chem. 2009, 9 (2) 148-62
22. Loryan, I.; Hammarlund-Udenaes, M. Drug Discovery Methods for Studying Brain Drug Delivery and Distribution. In Drug Delivery to the Brain; Hammarlund-Udenaes, M.; de Lange, E. C. M.; Thorne, R. G., Eds.; Springer: New York, 2014; Vol. 10, pp 271-316.
23. Winkler, E. A.; Sengillo, J. D.; Bell, R. D.; Wang, J.; Zlokovic, B. V. Blood-spinal cord barrier pericyte reductions contribute to increased capillary permeability J. Cerebral Blood Flow Metab. 2012, 32 (10) 1841-52
24. Ducharme, N.; Banks, W. A.; Morley, J. E.; Robinson, S. M.; Niehoff, M. L.; Mattern, C.; Farr, S. A. Brain distribution and behavioral effects of progesterone and pregnenolone after intranasal or intravenous administration Eur. J. Pharmacol. 2010, 641 (2-3) 128-34
25. Morley, J. E.; Banks, W. A. Lipids and cognition J. Alzheimers Dis. 2010, 20 (3) 737-47
26. Ertl, P.; Rohde, B.; Selzer, P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties J. Med. Chem. 2000, 43 (20) 3714-7
27. Threlkeld, S. W.; Lynch, J. L.; Lynch, K. M.; Sadowska, G. B.; Banks, W. A.; Stonestreet, B. S. Ovine proinflammatory cytokines cross the murine blood-brain barrier by a common saturable transport mechanism Neuroimmunomodulation 2010, 17 (6) 405-10
28. Ooms, F.; Weber, P.; Carrupt, P. A.; Testa, B. A simple model to predict blood-brain barrier permeation from 3D molecular fields Biochim. Biophys. Acta 2002, 1587 (2-3) 118-25
29. Wold, S.; Sjöströma, M.; Eriksson, L. PLS-regression: a basic tool of chemometrics Chemom. Intell. Lab. Syst. 2001, 58 (2) 109-130
30. Sheridan, R. P. Global quantitative structure-activity relationship models vs selected local models as predictors of off-target activities for project compounds J. Chem. Inf. Model. 2014, 54 (4) 1083-92
31. Hitchcock, S. A. Structural modifications that alter the P-glycoprotein efflux properties of compounds J. Med. Chem. 2012, 55 (11) 4877-95
32. Giacomini, K. M.; Huang, S. M.; Tweedie, D. J.; Benet, L. Z.; Brouwer, K. L.; Chu, X.; Dahlin, A.; Evers, R.; Fischer, V.; Hillgren, K. M.; Hoffmaster, K. A.; Ishikawa, T.; Keppler, D.; Kim, R. B.; Lee, C. A.; Niemi, M.; Polli, J. W.; Sugiyama, Y.; Swaan, P. W.; Ware, J. A.; Wright, S. H.; Yee, S. W.; Zamek-Gliszczynski, M. J.; Zhang, L. Membrane transporters in drug development Nat. Rev. Drug Discovery 2010, 9 (3) 215-36
33. Uchida, Y.; Ohtsuki, S.; Katsukura, Y.; Ikeda, C.; Suzuki, T.; Kamiie, J.; Terasaki, T. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors J. Neurochem. 2011, 117 (2) 333-45
34. Desai, P. V.; Sawada, G. A.; Watson, I. A.; Raub, T. J. Integration of in silico and in vitro tools for scaffold optimization during drug discovery: predicting P-glycoprotein efflux Mol. Pharmaceutics 2013, 10, 1249-61
35. Gantner, M. E.; Di Ianni, M. E.; Ruiz, M. E.; Talevi, A.; Bruno-Blanch, L. E. Development of conformation independent computational models for the early recognition of breast cancer resistance protein substrates Biomed. Res. Int. 2013, 2013, 863592
36. Hazai, E.; Hazai, I.; Ragueneau-Majlessi, I.; Chung, S. P.; Bikadi, Z.; Mao, Q. Predicting substrates of the human breast cancer resistance protein using a support vector machine method BMC Bioinf. 2013, 14, 130
37. Zhong, L.; Ma, C.-Y.; Zhang, H.; Yang, L.-J.; Wan, H.-L.; Xie, Q.-Q.; Li, L.-L.; Yang, S.-Y. A prediction model of substrates and non-substrates of breast cancer resistance protein (BCRP) developed by GA-CG-SVM method Comput. Biol. Med. 2011, 41 (11) 1006-13
38. Vassar, R.; Bennett, B. D.; Babu-Khan, S.; Kahn, S.; Mendiaz, E. A.; Denis, P.; Teplow, D. B.; Ross, S.; Amarante, P.; Loeloff, R.; Luo, Y.; Fisher, S.; Fuller, J.; Edenson, S.; Lile, J.; Jarosinski, M. A.; Biere, A. L.; Curran, E.; Burgess, T.; Louis, J. C.; Collins, F.; Treanor, J.; Rogers, G.; Citron, M. Beta-secretase cleavage of Alzheimers amyloid precursor protein by the transmembrane aspartic protease BACE Science 1999, 286 (5440) 735-41
39. Wang, Y.; Welty, D. F. The simultaneous estimation of the influx and efflux blood-brain barrier permeabilities of gabapentin using a microdialysis-pharmacokinetic approach Pharm. Res. 1996, 13 (3) 398-403
40. Hammarlund-Udenaes, M. Pharmacokinetic Concepts in Brain Drug Delivery. In Drug Delivery to the Brain; Hammarlund-Udenaes, M.; de Lange, E. C. M.; Thorne, R. G., Eds.; Springer: New York, 2014; Vol. 10, pp 127-161.
41. Liu, X.; Smith, B. J.; Chen, C.; Callegari, E.; Becker, S. L.; Chen, X.; Cianfrogna, J.; Doran, A. C.; Doran, S. D.; Gibbs, J. P.; Hosea, N.; Liu, J.; Nelson, F. R.; Szewc, M. A.; Van Deusen, J. Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding J. Pharmacol. Exp. Ther. 2005, 313 (3) 1254-62